Brokerages Anticipate Diplomat Pharmacy Inc (DPLO) Will Post Earnings of $0.24 Per Share
Brokerages expect that Diplomat Pharmacy Inc (NYSE:DPLO) will report earnings per share (EPS) of $0.24 for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $0.22 to $0.27. Diplomat Pharmacy posted earnings per share of $0.18 during the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The company is expected to report its next quarterly earnings results after the market closes on Monday, February 25th.
On average, analysts expect that Diplomat Pharmacy will report full year earnings of $0.81 per share for the current fiscal year, with EPS estimates ranging from $0.78 to $0.84. For the next fiscal year, analysts forecast that the firm will report earnings of $0.86 per share, with EPS estimates ranging from $0.77 to $1.02. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Diplomat Pharmacy.
Several equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 27th. ValuEngine downgraded shares of Diplomat Pharmacy from a “sell” rating to a “strong sell” rating in a report on Monday, February 4th. Mizuho dropped their target price on shares of Diplomat Pharmacy to $18.00 and set a “neutral” rating for the company in a report on Friday, November 9th. Wells Fargo & Co dropped their target price on shares of Diplomat Pharmacy from $23.00 to $16.00 and set a “market perform” rating for the company in a report on Thursday, November 8th. Finally, Robert W. Baird downgraded shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $22.00 to $10.00 in a report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.25.
NYSE:DPLO traded up $0.32 during mid-day trading on Monday, hitting $13.42. 373,232 shares of the company’s stock traded hands, compared to its average volume of 648,846. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58. Diplomat Pharmacy has a 1 year low of $12.30 and a 1 year high of $28.74. The company has a market capitalization of $989.71 million, a P/E ratio of 15.98 and a beta of 0.98.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Further Reading: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.